Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

NCT03221842 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
63
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early due to futility of enrolment and not for safety reasons.

Conditions

Interventions

Sponsor

CSL Behring